Top 5 Most Read RNS's on Vox Markets for Tuesday 4th October 2022

Episode 936,   Oct 04, 2022, 06:45 AM

Top 5 Most Read RNS's on Vox Markets for Tuesday 4th October 2022

5. N4 Pharma PLC #N4P - Double siRNA Testing Update

Announce successful in vitro testing of NuvecĀ® loaded with two small interfering RNA (siRNA) probes.

4. Poolbeg Pharma PLC #POLB - POLB 001 US Patent update

The US Patent and Trademarks Office, after reviewing a patent application that is directed to the use of POLB 001 and its homologues for the treatment of hypercytokinemia (or "cytokine storm"), has indicated to the Company that the main claim is allowable.

3. Union Jack Oil PLC #UJO - US$10m Net Revenues Landmark Reached at Wressle

Announce that material landmark net revenues of US$10,000,000 have been achieved from the Wressle hydrocarbon development, located within licences PEDL180 and PEDL182 in North Lincolnshire on the western margin of the Humber Basin.

Union Jack holds a 40% economic interest in this development.

2. Deepverge PLC #DVRG - Labskin contract

Labskin contract to develop revolutionary new approach to testing for radiation exposure. Collaboration with team of experts to develop new standards to protect military and civilians working or living near radiation sources. In a 3-year project worth $810k to the Company.

1. Synairgen plc #SNG - Data from the US NIH-led ACTIV-2 Phase 2 trial

Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19